Peter Pružinec1, Natalia Chirun2, Audrius Sveikata3. 1. Faculty of Medicine, Clinical Immunology & Allergology Cathedra, Slovak Medical University, Tabaková 1, 821 07 Bratislava, Slovak Republic. 2. NPO Petrovax Pharm, Moscow, Russian Federation. 3. Institute of Physiology & Pharmacology, Medical Academy, Lithuanian University of Health Science, Kaunas, Lithuania.
Abstract
AIM: This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS: A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety study was conducted in 15 healthcare centers in Slovakia. Adult patients who received commercially available Polyoxidonium 6 mg lyophilisate for solution for injection as a part of their routine care were observed for one cycle of treatment, consisting of five or ten injections. For safety assessment, adverse events were monitored with a special focus on signs or symptoms of potential adverse renal effects. At the end of the study, investigators and subjects rated the overall tolerance of Polyoxidonium treatment as well as improvement. Data collection was based on the review of medical records and routine examination of subjects. RESULTS: In total, 502 subjects were enrolled and 498 (99.2%) subjects completed the study. 19 (3.8%) subjects experienced a total of 34 adverse events. Only one (0.1%) subject experienced eight adverse drug reactions (ADRs): restlessness, fatigue, feeling hot (n = 2), pyrexia (n = 3) and asthenia. There were no renal ADRs or serious ADRs. At the end of the study, both investigators and subjects very positively rated global tolerability and global improvement. CONCLUSION: Polyoxidonium was well tolerated in the heterogenous population of patients, mostly with chronic recurrent bacterial or viral infections. No renal ADRs were reported in this postauthorization safety study, which was designed with a special focus on identifying potential adverse renal effects.
AIM: This study assessed the safety of Polyoxidonium® 6 mg lyophilisate for solution for injection in routine practice with a special focus on signs or symptoms of potential adverse renal effects. MATERIALS & METHODS: A local, multicenter, prospective, open-label, noninterventional, uncontrolled postauthorization safety study was conducted in 15 healthcare centers in Slovakia. Adult patients who received commercially available Polyoxidonium 6 mg lyophilisate for solution for injection as a part of their routine care were observed for one cycle of treatment, consisting of five or ten injections. For safety assessment, adverse events were monitored with a special focus on signs or symptoms of potential adverse renal effects. At the end of the study, investigators and subjects rated the overall tolerance of Polyoxidonium treatment as well as improvement. Data collection was based on the review of medical records and routine examination of subjects. RESULTS: In total, 502 subjects were enrolled and 498 (99.2%) subjects completed the study. 19 (3.8%) subjects experienced a total of 34 adverse events. Only one (0.1%) subject experienced eight adverse drug reactions (ADRs): restlessness, fatigue, feeling hot (n = 2), pyrexia (n = 3) and asthenia. There were no renal ADRs or serious ADRs. At the end of the study, both investigators and subjects very positively rated global tolerability and global improvement. CONCLUSION:Polyoxidonium was well tolerated in the heterogenous population of patients, mostly with chronic recurrent bacterial or viral infections. No renal ADRs were reported in this postauthorization safety study, which was designed with a special focus on identifying potential adverse renal effects.
Authors: Catherine Alexia; Mailys Cren; Pascale Louis-Plence; Dang-Nghiem Vo; Yasamine El Ahmadi; Emilie Dufourcq-Lopez; Zhao-Yang Lu; Javier Hernandez; Farkhad Shamilov; Olga Chernysheva; M Vasilieva; I Vorotnikov; Yana Vishnevskay; Nikolay Tupitsyn; Jean-François Rossi; Martin Villalba Journal: Front Immunol Date: 2019-11-28 Impact factor: 7.561
Authors: Sergey V Efimov; Natallia V Matsiyeuskaya; Olga V Boytsova; Lyudmila Yu Akhieva; Elena I Kvasova; Francisco Harrison; Yulia S Karpova; Anton Tikhonov; Nadezhda F Khomyakova; Tim Hardman; Jean-François Rossi Journal: Drugs Context Date: 2021-03-25
Authors: Sergey V Efimov; Natallia V Matsiyeuskaya; Olga V Boytsova; Luydmila Yu Akhieva; Elena V Kuntsevich; Anastasia A Troshina; Elena I Kvasova; Anton A Tikhonov; Nadezhda F Khomyakova; Francisco Harrison; Jean-François Rossi; Timothy C Hardman Journal: Drugs Context Date: 2022-03-03